July 2024 – Page 266 – Get News Story

Electroceuticals/Bioelectric Medicine Market worth $33.6 billion by 2029 | MarketsandMarkets™

“The major players in this market are Medtronic plc (Ireland), Boston Scientific Corporation (US), Abbott Laboratories, Inc. (US), LivaNova PLC (UK), Cochlear Ltd. (Australia), MicroPort Scientific Corporation (China)”

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall electroceuticals market and its subsegments.

Electroceuticals Market / Bioelectric Medicine Market in terms of revenue was estimated to be worth $23.9 billion in 2024 and is poised to reach $33.6 billion by 2029, growing at a CAGR of 7.0% from 2024 to 2029 according to a new report by MarketsandMarkets™. The increasing elderly population and rising incidences of cardiovascular and neurological disorders worldwide are driving the market’s growth. Bioelectric medicine employs deep brain, vagus sacral, and transcutaneous electric nerve stimulators to treat these conditions. Additionally, the growing prevalence of arrhythmia, which requires the use of implantable cardioverter-defibrillators and cardiac pacemakers, is another growth driver. The market is also benefiting from the growing demand for non-invasive medical treatments, technological advancements, and a growing body of research demonstrating the efficacy of this technology. The development of new, more advanced electroceutical devices and therapies, such as implantable neurostimulators and transcutaneous electrical nerve stimulation (TENS) devices, is further propelling market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222053956

The cardiac pacemakers & implantable cardioverter defibrillators segment accounted for the largest share of the electroceuticals market, by product segment, in 2022

Based on product, the electroceuticals market is segmented into cardiac pacemakers & implantable cardioverter defibrillators, neuromodulators, cochlear implants, and retinal implants. The cardiac pacemakers & implantable cardioverter defibrillators segment accounted for the largest share of the electroceuticals market in 2022, primarily due to the increasing prevalence of cardiovascular disorders worldwide. Additionally, the rising incidence of sudden cardiac arrests, a growing elderly population, and advancements in product development are anticipated to drive market growth.

Non-invasive electroceutical devices segment to register the highest growth rate during the forecast period

The electroceuticals market is divided into two segments: implantable electroceutical devices and non-invasive electroceutical devices. In 2022, the noninvasive electroceutical devices segment experienced the highest growth rate. This growth is attributed to factors such as increased R&D investments by companies for novel product development and technological advancements in this segment.

Arrhythmia segment accounted for the largest share of the electroceuticals market, by product segment, in 2022

Based on application, the electroceuticals market is segmented into arrhythmia, chronic pain management, Parkinson’s disease, urine incontinence, depression, epilepsy, and others. In 2022, the arrhythmia segment emerged as the dominant force in the overall market. This dominance is fueled by the rising prevalence of arrhythmia, a condition often managed with implantable cardioverter-defibrillators and cardiac pacemakers.

North America is the largest regional market for electroceuticals market

The global electroceuticals market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, North America held the largest market share in the electroceuticals market in 2022. A significant share in North America can be attributed to the presence of major medical device manufacturers like Abbott and Boston Scientific Corporation. The region’s well-established healthcare system and access to advanced products have further propelled market growth. Following North America, Europe secured the second position, fueled by the increasing demand for innovative medical devices for treatment. The region’s robust healthcare infrastructure and the presence of major bioelectric medicine manufacturers are expected to continue driving market growth.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=222053956

Electroceuticals Market / Bioelectric Medicine Market Dynamics:

Drivers:

The increasing elderly population and subsequent rise in the prevalence of neurological and cardiovascular disorder

Restraints:

The high cost associated with electroceutical devices

Opportunities:

Emerging markets present attractive opportunities

Challenge:

The shortage of skilled professionals

Key Market Players of Electroceuticals Market / Bioelectric Medicine Industry:

The major players in this market are Medtronic plc (Ireland), Boston Scientific Corporation (US), Abbott Laboratories, Inc. (US), LivaNova PLC (UK), Cochlear Ltd. (Australia), MicroPort Scientific Corporation (China), Sonova Group (Switzerland), Nevro Corp. (US), Axonics Modulation Technologies, Inc. (US), Neuronetics, Inc. (US), ElectroCore, Inc. (US), NeuroPace, Inc. (US), BIOTRONIK (Germany), Medico S.p.A. (Italy), Nurotron Biotechnology Co. Ltd. (US), MED-EL (Austria), Aleva Neurotherapeutics SA (Switzerland), NeuroSigma, Inc. (US), BioWave Corporation (US), Soterix Medical Inc. (US), Bioinduction (Amber Therapeutics) (UK), GiMer Medical (Taiwan), Cefaly (Belgium), BioControl Medical (Israel), and tVNS Technologies GmbH (Germany).

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 – 28%, Tier 2 – 42%, and Tier 3 -30%
By Designation: C-level – 30%, D-level – 34%, and Others – 36%
By Region: North America – 46%, Europe – 25%, Asia Pacific – 18%, and Rest of the World -11%

Recent Developments of Electroceuticals Market / Bioelectric Medicine Industry:

In January 2024, Medtronic plc (Ireland) received FDA approval of its Percept RC Deep Brain Stimulation (DBS) system.
In July 2023, Boston Scientific Corporation (US) received the US FDA approval for the vercise neural navigator 5 software, which when used as part of the vercise genus deep brain stimulation (dbs) systems.
In May 2023, Abbott (US) received US FDA approval for its spinal cord stimulation (SCS) devices for the treatment of chronic back pain.
In Dec 2022, ElectroCore (US) launched a new wellness product offering called Truvaga for customers residing in the US. Truvaga is a handheld non-invasive vagus nerve stimulator that utilizes our proven technology to activate the vagus nerve quickly and gently.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=222053956

Electroceuticals Market / Bioelectric Medicine Market – Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall electroceuticals market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/electroceutical-market-222053956.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Electroceuticals/Bioelectric Medicine Market worth $33.6 billion by 2029 | MarketsandMarkets™

GROKR Exchange: Leading the New Era of Digital Currency Trading

In today’s rapidly growing global digital currency market, GROKR Exchange has quickly emerged as a formidable force in the cryptocurrency trading sector, thanks to its innovative technology platform and comprehensive services. As a compliant platform regulated by the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN), GROKR Exchange has been committed to providing users with a secure, transparent, and efficient trading environment since its inception.

One of GROKR Exchange’s key advantages is the variety and number of trading pairs it supports. Currently, the platform supports over 253 cryptocurrencies, offering 512 trading pairs, covering nearly all mainstream and emerging digital assets in the market. This not only provides users with a wide range of investment options but also caters to investors with different risk preferences by offering personalized trading strategies. Whether one is a long-term investor seeking stability or an active trader favoring short-term transactions, GROKR Exchange has suitable trading opportunities.

Technology is another cornerstone of GROKR Exchange. The platform utilizes an advanced matching engine to ensure fast execution of trades and system stability. Additionally, GROKR Exchange has implemented multiple layers of security measures, including cold storage, multi-signature technology, and real-time monitoring systems, to safeguard users’ assets. These measures significantly reduce security risks during the trading process, providing robust protection for users’ funds.

Enhancing user experience is a continual goal for GROKR Exchange. The platform offers a user-friendly interface and intuitive operational processes, ensuring that both newcomers to cryptocurrency trading and seasoned traders can enjoy a seamless trading experience. Moreover, GROKR Exchange provides a wealth of educational resources and market analysis tools to help users better understand market dynamics and improve their analytical and decision-making abilities.

On February 18, 2022, GROKR Exchange achieved a remarkable milestone by reaching a trading volume of $117 million within 24 hours. This achievement not only demonstrates the platform’s strong liquidity and activity but also reflects its significant position in the global cryptocurrency market. This success is attributed to GROKR Exchange’s continuous investment in technology, user experience, and market expansion.

Looking ahead, GROKR Exchange plans to continue expanding its service range by adding more trading pairs and financial products to meet the growing market demand. The vision of GROKR Exchange is to build a global digital asset trading ecosystem that provides secure, reliable, and user-friendly services, enabling more people to participate in digital currency trading and share in the prosperity of the digital economy. With ongoing technological advancements and market growth, GROKR Exchange is steadily progressing towards this ambitious goal.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: GROKR Exchange Ltd.
Contact Person: ERNEST DEWEY MAY JR
Email: Send Email
Country: United States
Website: https://grokrlssc.com/

Mastering GST Billing: A Comprehensive Guide to Compliance and Efficiency

When it comes to managing your business, efficiency and compliance are paramount. One area where this is particularly crucial is GST billing. With the right approach and tools, you can streamline your processes, ensure compliance, and make your business operations smoother. Here are the essentials of GST billing and how you can master it with the help of GST billing software.

Why GST Billing Matters?

First, let’s understand why GST billing is so important. The Goods and Services Tax (GST) is a comprehensive, multi-stage, destination-based tax levied on every value addition. Businesses must comply with GST regulations to avoid penalties and ensure smooth operations. Proper GST billing not only ensures compliance but also improves transparency and accuracy in your financial transactions.

The Essentials of GST Billing

What is GST Billing?

GST billing involves generating invoices that comply with GST regulations. These invoices must contain specific details such as the supplier’s and recipient’s GSTIN, invoice number, date, taxable value, tax rate, and the amount of tax charged. Omitting any of these details can result in non-compliance issues.

Key Components of a GST Invoice

A proper GST invoice should include the following:

– Supplier’s Details:

Name, address, and GSTIN.

– Recipient’s Details:

Name, address, and GSTIN (if registered).

– Invoice Number:

A unique sequential number.

– Date:

The date of issue.

– Description of Goods/Services:

Provide a clear description with HSN/SAC codes.

– Taxable Value:

The value before tax.

– GST Rates:

Applicable CGST, SGST, and IGST rates.

– Total Amount:

This includes tax and any additional charges.

Importance of Accuracy

Accuracy in GST billing is non-negotiable. Errors can lead to penalties and complicate your tax filings. This is where the efficiency of GST billing software becomes evident. Such software ensures that all necessary details are captured and compliant with GST norms.

How GST Billing Software Enhances Efficiency

Automating the Process

One of the biggest advantages of using GST billing software is automation. It significantly reduces the time and effort required to generate invoices. This automation helps minimize human errors and ensures that your invoices are always correct.

Real-Time Updates

GST laws and rates can change. GST billing software usually comes with real-time updates, ensuring that your billing practices are always in line with the latest regulations. This feature saves you from the hassle of manually updating your billing system and reduces the risk of non-compliance.

Comprehensive Record-Keeping

Maintaining records is crucial for GST compliance. GST billing software helps you keep comprehensive records of all your transactions. These records are essential during audits and for filing returns. With all your invoices stored digitally, retrieving any information becomes a matter of seconds.

Choosing the Right GST Billing Software

Features to Look For

When choosing GST billing software, look for the following features:

– User-Friendly Interface:

Easy to navigate and use.

– Compliance Assurance:

Regular updates to stay compliant with GST laws.

– Customization:

Ability to customize invoices as per your business needs.

– Integration:

Seamless integration with your accounting software.

Conclusion

Mastering GST billing is essential for the smooth operation of your business. By understanding the key components of GST billing and leveraging GST billing software, you can ensure compliance, improve efficiency, and focus on what you do best – running your business. So, take the time to explore your options and choose the right GST billing software that fits your needs.

Media Contact
Company Name: CaptainBiz
Contact Person: Chetan Morajkar
Email: Send Email
Phone: 9833276867
Country: India
Website: https://www.captainbiz.com/

Quantmove Smart Markets releases a new data security protocol, significantly meeting the security needs of global users.

On July 1, Quantmove Smart Markets Limited (QSM) announced the release of its latest data security protocol, addressing the increasing demands of the digital age and significantly enhancing data security for its global users. This new protocol marks a substantial advancement in QSM’s commitment to data protection, aiming to provide users with state-of-the-art security assurance.

In today’s rapidly evolving digital economy and fintech landscape, data security is a critical concern for both users and businesses. QSM focuses on maximizing asset value for its clients through proprietary quantitative trading algorithms and an intelligent investment platform. With a growing user base and expanding transaction volumes, the importance of data security has never been more pronounced. Chris Weston, QSM’s external affairs representative, stated, “We understand the critical importance of data security to our users, and we are continually enhancing our security measures to ensure the highest level of protection for user transactions and data.”

The newly released data security protocol incorporates several innovative measures designed to significantly enhance the platform’s security performance. First, QSM has integrated advanced encryption technology to ensure that user data remains highly encrypted during both transmission and storage. Additionally, QSM has implemented multi-layer authentication mechanisms, including biometric verification and two-factor authentication, greatly enhancing account security. The company has also established real-time monitoring and alert systems to quickly detect and respond to any potential security threats, ensuring the platform’s stability and security.

To ensure the smooth implementation and promotion of the new protocol, QSM has launched a series of user education and training initiatives. The company uses online webinars, technical lectures, and platform announcements to help users understand and adopt the new security measures and operational guidelines. Additionally, QSM provides 24/7 customer support to promptly address any issues users may encounter during use.

The release of this data security protocol is a significant initiative in QSM’s technological innovation and user service strategy, underscoring the company’s strong commitment to user security and interests. Moving forward, QSM plans to continue investing heavily in security technology to maintain its technological edge, continuously enhancing the platform’s security and stability. Through ongoing technological innovation and service optimization, QSM is dedicated to providing the highest quality financial trading experience for users worldwide, helping them preserve and grow their assets.

In summary, QSM’s latest upgrade not only boosts platform security but also strengthens user trust and reliance. Financial analysts widely view QSM’s investment in data security favorably, believing it will increase the company’s competitiveness and user loyalty in the global market. If QSM continues to innovate technologically and improve user services, it could become a secure, stable, and leading international platform.

Media Contact
Company Name: Quantmove Smart Markets Limited
Contact Person: Lion
Email: Send Email
Country: United States
Website: https://www.qmovsi.com/

Minimally Invasive Surgery Market worth $173.9 billion by 2029

“North America is propelled by factors such as a growing aging population, a high incidence of chronic disorder, a rise in demand for minimally invasive surgical procedures, and the presence of strong players with robust minimally invasive surgery portfolios.”

Browse 310 market data Tables and 67 Figures spread through 359 Pages and in-depth TOC on “Minimally Invasive Surgery Market by Product (Robotics, Imaging, Instrument (Handheld, inflation, Guiding, electrosurgery, endoscopy)), Application (CVD, thoracic, neuro, ENT, OB/GYN, orthopedic), End-user, and Surgery volume – Global Forecast to 2029

The report “Minimally Invasive Surgery Market by Product (Robotics, Imaging, Instrument (Handheld, inflation, Guiding, electrosurgery, endoscopy)), Application (CVD, thoracic, neuro, ENT, OB/GYN, orthopedic), End-user, and Surgery volume – Global Forecast to 2029”, is projected to reach USD 173.9 billion by 2029 from USD 79.3 billion in 2024, growing at a CAGR of 17.0% during the forecast period. The expansion of the minimally invasive surgery market is propelled by several synergistic factors, including increasing demand for MIS procedures, escalating chronic disorder prevalence, increasing geriatric patient population, rising public-private investments to support for the clinical research and the presence of key market players in developing regions.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=787

Imaging & Visualization systems segment to register a significant growth rate over the forecast period of 2023-2029.

Based on the product, the minimally invasive surgery market is segmented into Surgical Devices, Imaging & Visualization Systems, Endoscopy Devices, Electrosurgical Devices, and Medical Robotics. The surge in chronic disorder and less invasive surgical procedures often involve imaging systems to visualize the affected area. Furthermore, these innovations provide surgeons with enhanced clarity and precision in observing the surgical site, resulting in reduced tissue trauma, shorter operative durations, expedited patient recovery, and improved overall outcomes.

Cardio-thoracic surgery segment accounted for the significant share of the minimally invasive surgery market in 2023-2029.

Based on the application, cardio-thoracic segment accounts largest market share in minimally invasive surgery market. Key drivers propelling the adoption of minimally invasive surgery (MIS) in cardio-thoracic procedures encompass technological advancements, particularly in precision surgical tools and imaging modalities. As clinicians accrue expertise in MIS methodologies, they exhibit greater confidence in applying these techniques to intricate cardio-thoracic interventions. Additionally, evolving healthcare policies and reimbursement frameworks incentivizing cost-effective and streamlined treatment pathways further bolster the uptake of MIS in cardio-thoracic surgery

North America to account for a significant market share in the minimally invasive surgery market in 2023.

Based on region, The minimally invasive surgery market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with North America dominating the market share in 2023. This dominance in North America is propelled by factors such as a growing aging population, a high incidence of chronic disorder, a rise in demand for minimally invasive surgical procedures, and the presence of strong players with robust minimally invasive surgery portfolios. Furthermore, growing research and funding initiatives from public and private organizations are expected to further boost the minimally invasive surgery market in North America.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=787

Minimally Invasive Surgery Market Dynamics:

Drivers:

1. Increase adoption of MIS over open surgeries

Restraints:

1. High cost of Robotic systems

Opportunities:

1. Emerging markets- growth opportunities

Challenge:

1. High degree of market consolidaton

Key Market Players of Minimally Invasive Surgery Industry:

As of 2023, prominent players in the minimally invasive surgery market are Medtronic (Ireland), Johnson & Johnson (US), NuVasive (US), Becton, Dickinson & Co. (US), Stryker Corporation (US), Zimmer Biomet Holdings (US), Abbott Laboratories (US) and Boston Scientific Corporation (US), GE healthcare (US), among others.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
By Designation: C-level– 27%, Director-level–18%, and Others–55%
By Region: North America–50%, Europe-20%, Asia Pacific–15%, Latin America–10%, and the Middle East & Africa–5%

Recent Developments of Minimally Invasive Surgery Industry:

In 2023, Medtronic receives CE Mark approval for Affera Mapping and Ablation System to treat atrial arrhythmias.
In 2023, J&J MONARCH Platform is the first minimally invasive, robotic-assisted technology approved for bronchoscopy in China with significant burden of lung cancer.
In 2023, Stryker’s Q Guidance System for cranial applications received US FDA clearance to support cranial surgeries.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=787

Minimally Invasive Surgery Market – Key Benefits of Buying the Report:

The report will help the new entrants/ market leaders/smaller firms in this market with investment evaluation viability within the minimally invasive surgery market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, challenges, growth catalysts and prospects, thereby empowering strategic decision-making with astute discernment.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Minimally Invasive Surgery Market worth $173.9 billion by 2029

Dengue Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Dengue- Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Dengue pipeline landscape. It covers the Dengue pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Dengue Research. Learn more about our innovative pipeline today! @ Dengue Pipeline Outlook

Key Takeaways from the Dengue Pipeline Report

June 2024:- Janssen Research & Development LLC- A Phase 2, Randomized, Double-blind, Placebo-controlled, Double-dummy, Multicenter Trial Assessing the Efficacy and Safety of Two Dose Regimens of JNJ-64281802 for the Prevention of Dengue Infection. The purpose of this study is to evaluate the prophylactic effect of JNJ-64281802 with respect to the prevention of laboratory-confirmed dengue virus (DENV) infection up to the last day of dosing among participants who have no evidence of current DENV infection at baseline.
June 2024:- Novartis Pharmaceuticals- A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever. The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
DelveInsight’s Dengue pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Dengue treatment.
The leading Dengue Companies such as Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.
Promising Dengue Therapies such as EYU688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV), and others.

Stay informed about the cutting-edge advancements in Dengue Treatments. Download for updates and be a part of the revolution in infectious disease care @ Dengue Clinical Trials Assessment

Dengue Emerging Drugs Profile

VIS 513: Visterra

VIS513, is a monoclonal antibody in development for the treatment of Dengue, a serious mosquito-borne virus, which in its most severe forms is characterized by uncontrolled bleeding leading to organ failure and death. VIS513 has in vitro and in vivo activity against all four Dengue virus serotypes found globally.

TAK-003: Takeda

Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses. Clinical Phase II data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegative participants, which persisted through 48 months after vaccination, and the vaccine was found to be generally safe and well tolerated.

CDX DENV: Codagenix

Codagenix has leveraged the platform to re-design contemporary strains of dengue and demonstrate a balanced tetravalent vaccine that is safe and immunogenic in primates. CDX DENV, is a Synthetic vaccine being developed in the Pre-Clinical stage for the treatment of Dengue.

AT 752: Atea Pharmaceuticals

AT-752, a diastomer of AT-527, is a novel purine nucleotide prodrug, designed to treat patients either newly infected or previously infected with the dengue virus. AT-752 has an favorable preclinical safety profile and has demonstrated potent in vitro activity against all dengue serotypes tested as well as potent antiviral activity in predictive animal models. Atea Pharmaceuticals plan to conduct clinical studies that will evaluate the daily administration of AT-752 over a short period of treatment, in order to negate the progression of infection and reduce the occurrence of life-threatening conditions associated with severe dengue.

Learn more about Dengue Drugs opportunities in our groundbreaking AL Dengue Research and development projects @ Dengue Unmet Needs

Dengue pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Dengue Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Discover the latest advancements in Dengue Treatment by visiting our website. Stay informed about how we’re transforming the future of infectious disease @ Dengue Market Drivers and Barriers, and Future Perspectives

Scope of the Dengue Pipeline Report

Coverage- Global
Dengue Companies- Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.
Dengue Therapies- EYU688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV), and others.
Dengue Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Dengue Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Dengue Pipeline on our website @ Dengue Drugs and Companies

Table of Content

Introduction
Executive Summary
Dengue: Overview
Pipeline Therapeutics
Therapeutic Assessment
Dengue– DelveInsight’s Analytical Perspective
Late Stage Products (Pre-Registration)
TAK-003: Takeda
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AT 752: Atea Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Dengue Key Companies
Dengue Key Products
Dengue- Unmet Needs
Dengue- Market Drivers and Barriers
Dengue- Future Perspectives and Conclusion
Dengue Analyst Views
Dengue Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dengue Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Netherton Syndrome Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Netherton Syndrome- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Netherton Syndrome Research. Learn more about our innovative pipeline today! @ Netherton Syndrome Pipeline Outlook

Key Takeaways from the Netherton Syndrome Pipeline Report

June 2024:- Daiichi Sankyo- A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome. This study will explore the safety, pharmacokinetics (PK), and early clinical signal efficacy of DS-2325a in adult patients with NS.
June 2024:- Boehringer Ingelheim- This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years and older. The purpose of this study is to find out whether a medicine called spesolimab helps people with NS.
DelveInsight’s Netherton Syndrome pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Netherton Syndrome treatment.
The leading Netherton Syndrome Companies such as TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharmaa, and others.
Promising Netherton Syndrome Therapies such as DS-2325a, QRX003, Spesolimab, and others.

Stay informed about the cutting-edge advancements in Netherton Syndrome Treatments. Download for updates and be a part of the revolution in genetic disorder care @ Netherton Syndrome Clinical Trials Assessment

Netherton Syndrome Emerging Drugs Profile

QRX003: Quoin Pharmaceuticals

QRX003 is a topical lotion, formulated with a proprietary Invisicare® delivery technology, and contains a broad- spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein, called LEKTI. The absence of LEKTI in Netherton patients leads to excessive skin shedding resulting in a highly porous and compromised skin barrier. QRX003 is designed to lead to a more normalized skin shedding process and the formation of a stronger and more effective skin barrier.

SXR-1096: Sixera Pharma

SXR1096 is a first-in-class, potent and selective small molecule inhibitor of kallikreins 5, 7 and 14 (KLK5, 7 and 14). The compound is formulated in a proprietary skin cream formulation designed for daily use in patients with rare skin conditions. Due to the inborn lack of the protease inhibitor LEKTI, KLK 5, 7 and 14 are overactive in the outermost layer of the skin in patients with Netherton syndrome. These drug targets can best be reached by applying the pharmaceutical directly on the skin. The disease is manifest from birth and can be life threatening in newborns.

Learn more about Netherton Syndrome Drugs opportunities in our groundbreaking Netherton Syndrome Research and development projects @ Netherton Syndrome Unmet Needs

Netherton Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Netherton Syndrome Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in Netherton Syndrome Treatment by visiting our website. Stay informed about how we’re transforming the future of genetic disorder @ Netherton Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Netherton Syndrome Pipeline Report

Coverage- Global
Netherton Syndrome Companies- TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharmaa, and others.
Netherton Syndrome Therapies- DS-2325a, QRX003, Spesolimab, and others.
Netherton Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Netherton Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Netherton Syndrome Pipeline on our website @ Netherton Syndrome Drugs and Companies

Table of Content

Introduction
Executive Summary
Netherton Syndrome: Overview
Pipeline Therapeutics
Therapeutic Assessment
Netherton Syndrome – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
QRX003: Quoin Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SXR-1096: Sixera Pharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Netherton Syndrome Key Companies
Netherton Syndrome Key Products
Netherton Syndrome- Unmet Needs
Netherton Syndrome- Market Drivers and Barriers
Netherton Syndrome- Future Perspectives and Conclusion
Netherton Syndrome Analyst Views
Netherton Syndrome Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Netherton Syndrome Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Synthetic Fuels Market Application, Growth, Opportunities, Top Companies, Share, Trends, Key Segments, Regional Insights, and Forecast to 2030

“Browse 163 market data Tables and 53 Figures spread through 228 Pages and in-depth TOC on “Synthetic Fuels Market””

The synthetic fuels market is growing due to energy security and environmental goals. It involves producing fuels like synthetic diesel and methane from renewable sources or carbon capture, contributing to global energy transition efforts.

The synthetic fuels market is projected to grow from USD 48.4 billion in 2023 to USD 70.1 billion by 2030, at a CAGR of 5.4% from 2023 to 2030. The market growth is expected to be driven by investment from private players boosting research & development, and diversification in the primary energy mix. High potential of different applications of synthetic fuels and introduction of carbon pricing mechanisms and tax credits for synthetic fuel production, and trying to make it financially viable by several governments worldwide may lead to major opportunities, fueling market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=15465529

Synthetic Fuels Companies

Companies such as Shell (UK), SASOL (South Africa), CHN Energy Investment Group Co., Ltd. (China), Chevron Renewable Energy Group (US), ExxonMobil Corporation (US), fall under the winners’ category. These are leading players in the synthetic fuels market, globally. These players have adopted the strategies of acquisitions, expansions, partnerships, and investments to increase their market shares.

Shell

Shell is a British multinational oil and gas company with operations in over 99 countries and around 44,000 service stations worldwide. The Business segments of Shell are as follows integrated gas, upstream, marketing, chemicals, and products, renewable and energy solutions & corporate. It is vertically integrated and active in every area of the oil and gas industry, including exploration, production, refining, transport, distribution, and marketing, petrochemicals, power generation, and trading. Shell is the second largest investor-owned oil and gas company globally and specializes in the management of oil and gas resources. The company has manufacturing plants across Durban, Canada, Texas, China, Malaysia, Singapore, Germany, Netherlands, the UK, and Qatar.

SASOL

SASOL operates as an international integrated chemicals and energy company. Its operations include commercializing technologies and developing a wide range of products, such as liquid fuels, chemicals, and low-carbon electricity. The company operates through Energy business (mining, gas, fuel) & Chemicals (Africa, America, Eurasia). SASOL bifurcates these business segments into two units, namely, strategic business units and operating business units. Strategic business units include energy, base chemicals, performance chemicals, and group functions, whereas operation business units include mining as well as exploration & production.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=15465529

CHN Energy Investment Group Co., Ltd.

CHN Energy Investment Group Co., Ltd. is a Chinese company that provides products and services of whole industrial chains including coal, electric power, transportation, and chemical industry. With the approval of the CPC Central Committee and the State Council, CHN Energy Investment Group (CHN Energy) was formally established, following the merger of China Guodian Corporation and Shenhua Group. Shenhua Ningxia Coal Industry Group Co., Ltd., a subsidiary of CHN Energy Investment Group, was formerly known as National Energy Group Ningxia Coal Industry Co., Ltd. The company has expertise in coal-based power generation and transmission, alongside the production of ammonia, ethanol, and sulfur-based chemical products. Its corporate headquarters is in Yinchuan, Ningxia, China. It is the world’s largest company in coal mining, thermal power, wind power, and coal-to-liquids industry. The company operates in 31 provinces, autonomous regions, and municipalities across China, as well as more than 10 countries and regions including the US and Canada.

Chevron Renewable Energy Group

Chevron Renewable Energy Group is a business segment of Chevron Corporation that focuses on growing Chevron’s portfolio of lower carbon fuels and developing new ones. The group was formed after Chevron completed its acquisition of Renewable Energy Group (REG) in June 2022. Chevron Renewable Energy Group is now one of the biggest bio-based diesel manufacturers by volume in the US. Chevron Renewable Energy Group combines REG’s feedstock aggregation capabilities with Chevron’s fuel distribution network to be a leader in the alternative fuels space. The group serves the transportation industry and offers cost-effective, lower carbon solutions that utilize today’s fleets and infrastructure.

Request Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=15465529

ExxonMobil Corporation

ExxonMobil Corporation, is one of a prominent multinational energy company which is a result of the merger between Exxon Corporation and Mobil Corporation. ExxonMobil Corporation is engaged in the exploration, production, transportation, and sale of crude oil, natural gas, and petroleum products. The company operates through four business segments, namely, upstream, energy products, chemical products, and specialty products. The company has a significant presence in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. ExxonMobil serves a diverse range of industries with its products, such as fuels, lubricants, and aviation products cater to the transportation sector, including automotive, aviation, and marine industries, vital raw materials for manufacturing plastics, packaging, and other industrial processes, it also plays a pivotal role in the energy production sector by manufacturing and distributing oil and natural gas petrochemical products are used in various industries for manufacturing goods like plastics and synthetic fibers, products for the agricultural sector, such as lubricants and fuels for agricultural machinery and processes.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/synthetic-fuels-market-15465529.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Synthetic Fuels Market Application, Growth, Opportunities, Top Companies, Share, Trends, Key Segments, Regional Insights, and Forecast to 2030

Bioplastics & Biopolymers Market Growth Analysis, Size, Opportunities, Top Companies, Trends, Key Segments, Regional Analysis, and Forecast to 2029

“Browse 261 market data Tables and 54 Figures spread through 318 Pages and in-depth TOC on “Bioplastics & Biopolymers Market””

The bioplastics and biopolymers market is rapidly expanding due to growing environmental concerns and regulations favoring sustainable materials. These bio-based alternatives to traditional plastics offer biodegradability, reduced carbon footprint, and versatile applications across industries, driving market growth and innovation globally.

The global Bioplastics & Biopolymers market size is anticipated to expand from USD 15.3 Billion in 2024 to USD 45.2 Billion by 2029, with a CAGR of 24.2% during 2024-2029. Key drivers include increased bioplastics usage in packaging, stringent waste management regulations in Europe, government emphasis on green procurement policies, prioritization of bio-based content, and consumer preference for eco-friendly plastic products.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=88795240

Bioplastics & Biopolymers Companies

Leading companies in the bioplastics & biopolymers market include NatureWorks LLC, Braskem, BASF SE, Total Energies Corbion, Versalis S.P.A, Biome Bioplastics Limited, Mitsubishi Chemical Group Corporation, Biotec Biologische Naturverpackungen GmbH & Co., Plantic Technologies Limited, and Toray Industries, Inc. These players have pursued growth strategies such as acquisitions, mergers, investments, and expansions over the past five years to enhance competitiveness and expand their customer base globally.

Europe is the largest consumer of bioplastics & biopolymers and the second-largest producer of bioplastics globally. Packaging industry is the largest end-use industry of bioplastics & biopolymers in Europe. The political and economic conditions have also driven the market penetration of bioplastics & biopolymers.

NatureWorks LLC, a major biopolymers supplier, is co-owned by Cargill and PTT Global Chemical. The company specializes in producing biopolymers from renewable sources like corn, starch, and vegetable oils. Its product range includes series for extrusion/thermoforming, injection molding, films & cards, fibers & nonwovens, and 3D printing. NatureWorks serves various industries such as beauty & household, construction, food service, electronics, medical, and hygiene across North America, Europe, Japan, and Asia-Pacific. It operates manufacturing facilities in Blair, Nebraska, with a capacity of 150,000 metric tons of ingeo biopolymer.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=88795240

BASF SE, a prominent chemical company, operates across six business segments: chemicals, materials, industrial solutions, surface technologies, nutrition & care, and agricultural solutions. It offers biodegradable plastics through its materials segment and conducts research in process research & chemical engineering, advanced materials & systems research, and bioscience research. Serving over 90,000 customers globally, BASF holds a top-three market position in approximately 30% of its active business areas. With six Verbund sites and 232 additional production sites worldwide, the company operates extensively across Europe, Asia Pacific, North America, South America, Central America, and the Middle East & Africa.

Another significant player in the Bioplastics & Biopolymers sector is TotalEnergies Corbion. TotalEnergies Corbion, established in 2017 as a joint venture between Total Energies and Corbion, holds a prominent position in the PLA and lactide monomers market globally. Their Luminy PLA portfolio encompasses products across four categories suitable for various conversion technologies. They provide a range of solutions to sectors such as packaging, automotive, consumer goods, and textiles. Operating a PLA production facility capable of producing 75,000 tons per year in Rayong, Thailand, the company has a presence in North America, Asia-Pacific, and Europe.

Inquire Now: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=88795240

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bioplastics & Biopolymers Market Growth Analysis, Size, Opportunities, Top Companies, Trends, Key Segments, Regional Analysis, and Forecast to 2029

Måneskin Store Releases Electrifying New Merchandise Collection for fans of the Italian rock band

The merch has been created to help fans show their love for the band behind hits like I wanna be your Slave.

Maneskin Store has launched an exhilarating new collection of merchandise for fans of the chart-topping Italian rock band. This trendy range caters to Måneskin enthusiasts worldwide and offers an extensive array of products that capture the band’s rebellious spirit and iconic style.

A senior spokesperson for the Måneskin Store expressed excitement about the release, “Måneskin has captivated audiences worldwide with their electrifying performances, genre-blending sound, and unapologetic attitude. Fans are drawn to the band’s raw energy, powerful vocals, and ability to blend rock, glam, and pop influences seamlessly. The group’s meteoric rise to international stardom following their Eurovision victory has solidified their position as one of the most exciting acts in contemporary rock music. We’re excited to offer fans this new collection that embodies Måneskin’s dynamic energy and unique style.”

The new collection features a diverse selection of items, including apparel, accessories, and collectibles, including the stylish Maneskin shirt and Maneskin Hoodie adorned with the band’s logo, album artwork, and memorable lyrics. Fans can get their hands on merch for all the band members, including bassist Victoria De Angelis, lead vocalist Damiano David, drummer Ethan Torchio, and guitarist Thomas Raggi. The items shine light on Måneskin’s bold and glamorous aesthetic, from their iconic “doodle faces” design to provocative slogans.

He went on to add, “The overwhelming demand for Måneskin merchandise reflects the deep connection fans feel with the band. Our new collection allows fans to express their love for Måneskin’s music and embody their rebellious spirit in their everyday lives. All items in the new collection have been created using high-quality materials to make sure they last for a long time. With Måneskin’s growing global fanbase, this new merchandise collection arrives at the perfect time for fans to show their support for the band. The trendy collection offers something special for everyone, inviting fans to immerse themselves in the electrifying world of rock’s newest superstars. From our high-quality apparel to exclusive accessories, there’s something for every Måneskin enthusiast to enjoy and connect with their favorite band.”

Fans interested in checking out the collection can visit the website today at https://maneskin-merch.com/.

Media Contact
Company Name: Maneskin Store
Contact Person: Jerry Tim
Email: Send Email
Address:620 Baldock Drive
City: Mcleans Ridges
State: NSW 2480
Country: Australia
Website: https://maneskin-merch.com/